Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

Abstract Purpose To assess the incidence of BCR‐ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP‐CML) patients treated with tyrosine kinase inhibitors (TKIs). Patients and Methods We analyzed characteristics and outcome of 253 CP...

Full description

Bibliographic Details
Main Authors: Gabriel Etienne, Stéphanie Dulucq, Françoise Huguet, Anna Schmitt, Axelle Lascaux, Sandrine Hayette, Marie‐Pierre Fort, Pierre Sujobert, Fontanet Bijou, Stéphane Morisset, Suzanne Tavitian, Audrey Bidet, Beatrice Turcq, Fanny Robbesyn, Claudine Chollet, Francis Belloc, Françoise Durrieu, François‐Xavier Mahon, Franck E. Nicolini
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
BCR-ABL kinase domain mutation
chronic myeloid leukemia
tyrosine kinase inhibitors
Online Access:https://doi.org/10.1002/cam4.2410

Internet

https://doi.org/10.1002/cam4.2410

Similar Items